<DOC>
	<DOCNO>NCT01076192</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety adalimumab use routine clinical practice adult patient moderate severe chronic plaque psoriasis Spain .</brief_summary>
	<brief_title>Study Adalimumab ( HUMIRAÂ® ) Patients With Moderate Severe Psoriasis ( PS ) Spain ( PROMISE )</brief_title>
	<detailed_description>PROMISE 2 year post-authorization study patient take adalimumab Psoriasis . Patients volunteer participate ask provide information medical history experience adalimumab . No study specific test perform . Patients ask provide data experience adalimumab approximately every 6 month , determine study doctor . No drug provide result participation registry . All treatment decision independent participation registry . A total 547 subject enrol : 532 ITT population analyze efficacy ( exclude 15 lack follow-up visit ( n=8 ) , non-fulfillment criterion moderate severe PS ( n=6 ) failure initiate treatment baseline visit ( n=1 ) ) ; 542 analyze safety ( exclude 5 due lack evaluable safety data ) .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patient 18 year age old . Patient diagnose moderate severe chronic plaque PS begin treatment adalimumab accordance authorize condition use . Patient give informed consent writing . Patients treat accordance local product label Patient participate go participate clinical trial study followup Patient difficulty adequately read , understand complete questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Moderate Psoriasis</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Severe Psoriasis</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Safety</keyword>
	<keyword>Clinical practice</keyword>
</DOC>